7Suppliers
11Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Xeris Biopharma Holdings, Inc. (XERS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

22Total relationships
2Distinct source URLs
4High confidence
0.725Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Xeris Biopharma Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
CORT Corcept Therapeutics Incorporated 72% Reciprocal relationship from CORT graph: range of disorders, including central serous retinopathy, post-traumatic stress disorder, anxiety, alcoholism, cocaine addiction, Alzheimer’s disease, ALS, hy…
CORT Corcept Therapeutics Incorporated 72% duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from XERS graph: completion of extensive preclinical laboratory tests, animal studies and formulation studies in accordance with appl…
ORANY ORANY 72% completion of extensive preclinical laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including the FDA’s Good Laboratory Practice ("GLP") regulation…
TEVJF Teva Pharmaceutical Industries Limited 72% Reciprocal relationship from TEVJF graph: Reciprocal relationship from XERS graph: Reciprocal relationship from TEVJF graph: Reciprocal relationship from XERS graph: duct in Gvoke HypoPen is a propri…
TEVJF Teva Pharmaceutical Industries Limited 72% duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
BBNX Beta Bionics, Inc. 62% Reciprocal relationship from BBNX graph: Reciprocal relationship from XERS graph: Reciprocal relationship from BBNX graph: Reciprocal relationship from XERS graph: Reciprocal relationship from BBNX g…

Xeris Biopharma Holdings, Inc. Customers

TickerNameConfidenceEvidence
CORT Corcept Therapeutics Incorporated 72% Reciprocal relationship from CORT graph: ol synthesis inhibitor osilodrostat to treat patients with Cushing’s disease, which approval was broadened in April 2025 to include adult patients with any et…
CORT Corcept Therapeutics Incorporated 72% duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from XERS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from XERS graph: duct in Gvoke HypoPen is a propri…
ORANY ORANY 72% duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
TEVJF Teva Pharmaceutical Industries Limited 72% duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
TEVJF Teva Pharmaceutical Industries Limited 72% Reciprocal relationship from TEVJF graph: Reciprocal relationship from XERS graph: duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC…
SOMERSET-THERAPEUTICS-LLC SOMERSET-THERAPEUTICS-LLC 62% hree months ended March 31, 2026 and 2025 as well as factors that impact those items. Product revenue, net Product revenue, net, represents gross product sales less estimated allowances for patient c…
STRONGBRIDGE-DUBLIN-LIMITED STRONGBRIDGE-DUBLIN-LIMITED 62% hree months ended March 31, 2026 and 2025 as well as factors that impact those items. Product revenue, net Product revenue, net, represents gross product sales less estimated allowances for patient c…
TARO-PHARMACEUTICALS-NORTH-AMERICA-INC TARO-PHARMACEUTICALS-NORTH-AMERICA-INC 62% vements are limited by the expected lease term, which includes renewal options reasonably certain to be exercised. The majority of the Company's real estate leases require that the Company pay mainte…
TORRENT-PHARMACEUTICALS-LIMITED TORRENT-PHARMACEUTICALS-LIMITED 62% hree months ended March 31, 2026 and 2025 as well as factors that impact those items. Product revenue, net Product revenue, net, represents gross product sales less estimated allowances for patient c…
XERIS-PHARMACEUTICALS-INC XERIS-PHARMACEUTICALS-INC 62% hree months ended March 31, 2026 and 2025 as well as factors that impact those items. Product revenue, net Product revenue, net, represents gross product sales less estimated allowances for patient c…

Xeris Biopharma Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
XERS-DEBT Debt stack $252.6M 90% Market cache reports total debt of $252.6M.
XERS-DEBT-13654 Warrants outstanding: 2275313 90% xbrl warrant detail from xbrl 2026-01-31.
XERS-DEBT-13655 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Xeris Biopharma Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Xeris Biopharma Holdings, Inc..

Xeris Biopharma Holdings, Inc. Ownership

HolderNameConfidenceEvidence
XERS-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 240 tracked holders.

Xeris Biopharma Holdings, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
TEVJF Teva Pharmaceutical Industries Limited 100.00 1 ['customer', 'supplier']
ORANY ORANGE 100.00 1 ['customer', 'supplier']
BBNX Beta Bionics, Inc. 100.00 1 ['supplier']
AMZE Amaze Holdings, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
EQR Equity Residential 50.00 2
ALVO Alvotech 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
AZN AstraZeneca PLC 50.00 2
DWTX Dogwood Therapeutics, Inc. 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
🔐
XERS
Unlock XERS Supply Chain Data
Verified relationships include:
CORTCorcept Therapeutics Inco…Supplier72%
CORTCorcept Therapeutics Inco…Supplier72%
CORTCorcept Therapeutics Inco…Customer72%
CORTCorcept Therapeutics Inco…Customer72%
+18 more relationships locked
Subscribe — View plans →